Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹440.65
-₹8.10(-1.84%)
At close: 4:00 PM EDT
₹440.65
-₹8.10(-1.84%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹647.50
Previous CloseN/A
Volume125.06K
Average Volume (3M)12.44K
Market Cap
₹25.80B
Enterprise Value₹32.19B
Total Cash (Recent Filing)₹744.00M
Total Debt (Recent Filing)₹236.60M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding61,250,744
10 Day Avg. Volume14,140
30 Day Avg. Volume12,438
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsPanacea’s mix of branded formulations, vaccines and collaboration/contract-manufacturing revenues provides durable diversification. Multiple sales channels (private, institutional tenders, partners) reduce reliance on any single product or market, smoothing revenue across tender cycles and supporting medium-term resilience.
Vertical Integration (R&D To Commercialization)In-house development, manufacturing and commercialization create a structural advantage: faster product launches, tighter quality/regulatory control for vaccines, and the ability to capture manufacturing margins. This integration supports sustained competitive positioning and operational control over the next several months.
Conservative Balance Sheet / Low LeverageVery low leverage and sizable, stable equity provide financial flexibility to fund working capital, capex or development programs without immediate external funding. This conservatism helps absorb cash-flow variability, participate in tenders and support strategic initiatives over a multi-month horizon.
Bears Say
Persistent Negative Free Cash FlowConsistent negative free cash flow across FY2022–FY2026 indicates the business has been consuming cash despite an operating improvement in FY2026. Ongoing FCF deficits constrain reinvestment, raise dependence on the balance sheet or external financing, and limit the company's ability to self-fund growth or absorb shocks.
Ongoing Operating LossesContinued negative EBIT and net income in FY2026 show revenue growth has not yet converted to sustainable profits. Persistent losses weaken the firm's capacity to compound equity value, reduce internal funding for R&D or capex, and increase pressure to fix margins or alter strategy over the medium term.
Margin Volatility And Weak ReturnsErratic margins and an isolated profitable year (FY2022) that failed to persist point to unstable returns. This volatility complicates forecasting, undermines predictability of cash flows and investment returns, and suggests structural issues with product mix, pricing power or cost control that must be addressed for durable improvement.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹647.50 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹25.80B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on May 30, 2026. The company reported ₹0.08 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.08.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.399%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Piramal Pharma Limited
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―